

Applicants: Dean Engelhardt *et al.*
Serial No.: 08/486,066
Filed: June 7, 1995
Page 2 (Amendment After Final Office Action and
Request for One-Month Extension
of Time - July 20, 1998)

A response to the Final Office Action was originally due by June 8, 1998. Accordingly, Applicants hereby request a one-month extension of time, to and including July 18, 1998, in which to respond to the March 18, 1998 Office Action and authorize charge of the requisite fee to Deposit Account No. 05-1135. Therefore, the due date for filing a response to the March 18, 1998 Office Action is now July 18, 1998 and as July 18 is a Saturday, this Amendment is timely filed.

AMENDMENTS

Please amend the subject application as set forth below.

In the Claims

Amend the claims 238, 272 and 308 to read as follows:

-- 238. (Thrice amended) An oligo- or polynucleotide comprising at least one nucleotide

having the formula:




wherein PM is a phosphate moiety, SM is a sugar moiety comprising a pentose sugar selected from a ribose or a deoxyribose, and BASE is a pyrimidine, purine or 7-deazapurine moiety, said PM being covalently attached to the C2' or the C3' or the C5' position of SM, said BASE being covalently attached to the 1' position of SM from the N¹ position when BASE is a

Applicants: Dean Engelhardt *et al.*
Serial No.: 08/486,066
Filed: June 7, 1995
Page 3 (Amendment After Final Office Action and
Request for One-Month Extension
of Time - July 20, 1998)


L1
M1
pyrimidine or the N⁹ position when BASE is a purine or 7-deazapurine, and said Sig is [a detectable moiety] covalently attached to the C2 ' or the C3 ' or the C5 ' position of SM directly or through a linkage group and Sig is a moiety which is detectable when said nucleotide is incorporated into a double-stranded nucleic acid duplex. --

-- 272. (Thrice amended) A nucleotide having the formula:



wherein PM is a phosphate moiety, SM is a sugar moiety comprising a pentose sugar selected from a ribose or a deoxyribose, and BASE is a pyrimidine, purine or 7-deazapurine moiety, said PM being covalently attached to the C2 ' or the C3 ' or the C5 ' position of SM, said BASE being covalently attached to the 1' position of SM from the N¹ position when BASE is a pyrimidine or the N⁹ position when BASE is a purine or 7-deazapurine, and said Sig is [a detectable moiety] covalently attached to the C2 ' or the C3 ' or the C5 ' position of SM directly or through a linkage group and Sig is a moiety which is detectable when said nucleotide is incorporated into a double-stranded nucleic acid duplex. --

L3
M3
-- 308. (Thrice amended) A composition comprising a polymeric compound having attached directly or indirectly thereto at least one nucleotide having the formula:



Applicants: Dean Engelhardt *et al.*
Serial No.: 08/486,066
Filed: June 7, 1995
Page 4 (Amendment After Final Office Action and
Request for One-Month Extension
of Time - July 20, 1998)

13
canceled

wherein PM is a phosphate moiety, SM is a sugar moiety comprising a pentose sugar selected from a ribose or a deoxyribose, and BASE is a pyrimidine, purine or 7-deazapurine moiety, said PM being covalently attached to the C2' or the C3' or the C5' position of SM, said BASE being covalently attached to the 1' position of SM from the N¹ position when BASE is a pyrimidine or the N⁹ position when BASE is a purine or 7-deazapurine, and said Sig is [a detectable moiety] covalently attached to the C2' or the C3' or the C5' position of SM directly or through a linkage group and Sig is a moiety which is detectable when said nucleotide is incorporated into a double-stranded nucleic acid duplex. --

Kindly cancel claims 239, 273 and 309.

REMARKS

Applicants respectfully request the amendments to the claims set forth above be considered and entered and that the application and its rejection be reconsidered in view of the amendments and the following remarks.

The claims are 238-297 and 299-338. By entry of this amendment, claims 239, 273 and 309 are canceled, without prejudice, and claims 238, 272 and 308 are amended to more clearly and particularly define Applicants' invention. Accordingly, with entry of this amendment, the claims are 238, 240-272, 274-297, 308 and 310-338.

Claims 238, 272, and 308 are amended to include the recitations that the PM moiety and the Sig moiety are attached to "the C² or the C³ or the C⁵ position of" the sugar moiety SM. This